Dr Jay Feingold joins Daiichi Sankyo
pharmafile | February 19, 2010 | Appointment | Research and Development | Daiichi Sankyo, appointment, research and development
Daiichi Sankyo’s US arm has appointed Dr Jay Feingold vice president of medical affairs.
In this role his will manage strategic direction of the company’s medical affairs department and oversee more than 90 scientists, researchers and field-based medical teams.
He most recently worked with Wyeth Pharmaceuticals, where he most recently led oncology global clinical development.
Prior to that, he was multi-therapeutic area head in global medical affairs with responsibility for the haematology, oncology and central nervous system (CNS) franchises.
“I am very excited to join Daiichi Sankyo and look forward to working with my colleagues to continue to build relationships with health care providers to improve medical care and enhance professional education,” said Dr Feingold. “As we develop new and innovative therapies it will be important to ensure that critical safety and efficacy information is understood by practitioners, regulatory agencies, payors and patients. Medical Affairs plays a key role in communicating this information.”
Dr Feingold also becomes a member of Daiichi Sankyo Inc’s (DSI) executive committee, which is responsible for guiding the organisation’s short- and long-term strategic and financial objectives.
DSI is the US subsidiary of Tokyo-based Daiichi Sankyo and has two New Jersey locations – headquarters that house 480 employees and a clinical development division that employs 350 people who oversee clinical trials being conducted around the world.
Related Content
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
